Synopsis: Mylan exited Biocon by selling a 5.64 percent stake worth Rs. 3,678.68 crore, with ICICI Prudential Mutual Fund, Societe Generale, and Goldman Sachs among the key buyers.
This Mid-Cap Pharma Stock, engaged in the research, development, manufacturing, and commercialization of biopharmaceuticals, biosimilars, generic formulations, and specialty pharmaceutical products for global healthcare markets, is in focus after a Rs. 3,679 Crore Stake Sale to Goldman Sachs, Societe Generale, Morgan Stanley, and other mutual funds.
With a market capitalization of Rs. 71,149.75 crore, the shares of Biocon Limited were currently trading at Rs. 438.95 per equity share, rising nearly 0.38 percent from its previous day’s close price of Rs. 437.30.
What is the News?
Biocon witnessed a major block deal on July 14, 2026, as Mylan Inc. exited its entire holding in the company. Mylan sold 9.19 crore shares, representing a 5.64 percent stake, at Rs. 400 per share, taking the total transaction value to approximately Rs. 3,678.68 crore. The stake sale was executed through multiple block deal transactions on the NSE and BSE.
Several domestic and global institutional investors picked up the shares. ICICI Prudential Mutual Fund bought 1.84 crore shares worth about Rs. 737.50 crore, while HDFC Mutual Fund and Kotak Mahindra Mutual Fund each acquired 57.67 lakh shares, investing around Rs. 230.66 crore each. SBI Mutual Fund purchased 31.25 lakh shares valued at nearly Rs. 125 crore.
Among other notable buyers, Franklin Templeton Mutual Fund and Mirae Asset Mutual Fund bought 9.38 lakh shares each for around Rs. 37.50 crore. ICICI Prudential Life Insurance Company acquired 12.50 lakh shares worth Rs. 50 crore, while Societe Generale purchased 16.25 lakh shares valued at approximately Rs. 65 crore. Goldman Sachs Bank Europe SE acquired 6.26 lakh Biocon shares at Rs. 400 per share, investing approximately Rs. 25.04 crore through the block deal.
Other investors participating in the transaction included Abakkus Growth Fund, WhiteOak Capital Mutual Fund, Aditya Birla Sun Life Mutual Fund, Axis Mutual Fund, HDFC Life Insurance Company, Morgan Stanley, Eastspring Investments, Vanguard Emerging Markets Shares Index Fund, and several other institutional investors, reflecting broad participation in one of the largest block deals in Biocon this year.
Business Highlights
Biocon has built a strong global presence with a more than 47-year legacy, serving customers in more than 120 countries. The company operates 11 manufacturing locations and has established itself as a trusted partner for leading global pharmaceutical companies through its integrated research, development, and manufacturing capabilities.
The company has received more than 215 cGMP approvals from global regulatory authorities and has a portfolio of more than 1,500 patents. Biocon also provides services to 16 of the world’s top 20 pharmaceutical companies, highlighting its strong industry relationships, innovation capabilities, and global manufacturing expertise.
Company Overview
Biocon Limited is an Indian biopharmaceutical company headquartered in Bengaluru. Founded in 1978, it has grown into one of India’s largest biotechnology companies, developing and manufacturing biosimilars, generic active pharmaceutical ingredients (APIs), and other biopharmaceutical products that reach patients in more than 120 countries.
Recent Quarter Results
Coming into financial highlights, Biocon Limited’s revenue has increased from Rs. 4,417 crore in Q4 FY25 to Rs. 4,517 crore in Q4 FY26, which has grown by 2.26 percent. The net profit has decreased by 56.64 percent from Rs. 459 crore in Q4 FY25 to Rs. 199 crore in Q4 FY26.
Biocon Limited’s revenue has grown at a CAGR of 19 percent over the last five years. In terms of return ratios, the company’s ROCE and ROE stand at 3.75 percent and 1.40 percent, respectively. Biocon Limited has an earnings per share (EPS) of Rs. 2.38, and its debt-to-equity ratio is 0.45x.
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
